臨床検査56巻7号

2012年07月発行

今月の主題 周産期の臨床検査 各論

妊娠高血圧症候群の発症予知マーカー

著者： 竹中慎¹ 関沢明彦¹ 小出馨子¹ 岡井崇¹

所属機関： ¹昭和大学医学部産婦人科学教室

ページ範囲：P.761 - P.769

妊娠高血圧症候群(PIH)の発症の主な原因は，妊娠初期における胎盤形成不全による絨毛細胞傷害，そして絨毛細胞および各種生成物質の母体血中への流入，それらの物質による母体血管内皮細胞障害であると推測されている．母体へ流入する物質は，絨毛細胞由来cell-free DNA，血管新生関連因子，それをコードするcell-free RNA，絨毛細胞と絨毛細胞内のcellular RNAなど様々である．臨床症状が出現するかなり前からPIHの病態は完成されているため，これらの物質は妊娠初期から母体血中に流入している．早期からのこれらの物質の濃度などの変化を検出することでPIHの発症予知が可能である．

参考文献

1) Maynard S, Epstein FH, Karumanchi SA, et al : Preeclampsia and angiogenic imbalance. Annu Rev Med　59：61-78，2008

2) Pijnenborg R : The placental bed. Hypertens Pregnancy　15：7-23，1996

3) Reister F, Frank HG, Heyl W, et al : The distribution of macrophages in spiral arteries of the placental bed in pre-eclampsia differs from that in healthy patients. Placenta　20：229-233，1999

4) Pazmany L, Mandelboim O, Valés-Gómez M, et al : Protection from natural killer cell-mediated lysis by HLA-G expression on target cells. Science　274：792-795，1996

5) Sekizawa A, Farina A, Sugito Y, et al : Proteinuria and hypertension are independent factors affecting fetal DNA values : a retrospective analysis of affected and unaffected patients. Clin Chem　50：221-224，2004

6) Farina A, Sekizawa A, Sugito Y, et al : Fetal DNA in maternal plasma as a screening variable for preeclampsia. A preliminary nonparametric analysis of detection rate in low-risk nonsymptomatic patients. Prenat Diagn　24：83-86，2004

7) Sekizawa A, Farina A, Koide K, et al : beta-globin DNA in maternal plasma as a molecular marker of pre-eclampsia. Prenat Diagn　24：697-700，2004

8) Farina A, Sekizawa A, Iwasaki M, et al : Total cell-free DNA (β-globin gene) distribution in maternal plasma at the second trimester : a new prospective for preeclampsia screening. Prenat Diagn　24：722-726，2004

9) Li H, Gu B, Zhang Y, et al : Hypoxia-induced increase in soluble Flt-1 production correlates with enhanced oxidative stress in trophoblast cells from the human placenta. Placenta　26：210-217，2005

10) Maynard SE, Min JY, Merchan J, et al : Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest　111：649-658，2003

11) Venkatesha S, Toporsian M, Lam C, et al : Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med　12：642-649，2006

12) Levine RJ, Maynard SE, Qian C, et al : Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med　350：672-683，2004

13) Levine RJ, Lam C, Qian C, et al : Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med　355：992-1005，2006

14) Park CW, Park JS, Shim SS, et al : An elevated maternal plasma, but not amniotic fluid, soluble fms-like tyrosine kinase-1 (sFlt-1) at the time of mid-trimester genetic amniocentesis is a risk factor for preeclampsia. Am J Obstet Gynecol　193：984-989，2005

15) Wathén KA, Tuutti E, Stenman UH, et al : Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation. J Clin Endocrinol Metab　91：180-184，2006

16) Levine RJ, Thadhani R, Qian C, et al : Urinary placental growth factor and risk of preeclampsia. JAMA　293：77-85，2005

17) Poon LL, Leung TN, Lau TK, et al : Presence of fetal RNA in maternal plasma. Clin Chem　46：1832-1834，2000

18) Valadi H, Ekström K, Bossios A, et al : Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol　9：654-659，2007

19) Purwosunu Y, Sekizawa A, Koide K, et al : Cell-free mRNA concentrations of plasminogen activator inhibitor-1 and tissue-type plasminogen activator are increased in the plasma of pregnant women with preeclampsia. Clin Chem　53：399-404，2007

20) Purwosunu Y, Sekizawa A, Okazaki S, et al : Prediction of preeclampsia by analysis of cell-free messenger RNA in maternal plasma. Am J Obstet Gynecol　200：386．e1-7，2009

21) Okazaki S, Sekizawa A, Purwosunu Y, et al : Measurement of mRNA of trophoblast-specific genes in cellular and plasma components of maternal blood. J Med Genet　43：e47，2006

22) Nakamura M, Sekizawa A, Purwosunu Y, et al : Cellular mRNA expressions of anti-oxidant factors in the blood of preeclamptic women. Prenat Diagn　29：691-696，2009

23) Farina A, Zucchini C, Sekizawa A, et al : Performance of messenger RNAs circulating in maternal blood in the prediction of preeclampsia at 10-14 weeks. Am J Obstet Gynecol　203：575．e1-7，2010

24) Farina A, Morano D, Arcelli D, et al : Gene expression in chorionic villous samples at 11 weeks of gestation in women who develop preeclampsia later in pregnancy : implications for screening. Prenat Diagn　29：1038-1044，2009